<ARTICLE> 5 <LEGEND> Financial Data Schedule Mylan Laboratories Inc. and Subsidiaries Article 5 of Regulation S-X The schedule contains summary financial information extracted from the Consolidated Balance Sheet at December 31, 2000 and the Consolidated Statement of Earnings for the three months ended December 31, 2000 and is qualified in its entirety by reference to such financial statements. </LEGEND> <CIK> 0000069499 <NAME> none <PERIOD-TYPE> 9-MOS <FISCAL-YEAR-END> MAR-31-2001 <PERIOD-END> Dec-31-2000 <CASH> 212,397 <SECURITIES> 33,953 <RECEIVABLES> 307,090 <ALLOWANCES> 102,731 <INVENTORY> 178,067 <CURRENT-ASSETS> 783,519 <PP&E> 292,377 <DEPRECIATION> 118,742 <TOTAL-ASSETS> 1,397,273 <CURRENT-LIABILITIES> 266,677 <BONDS> 25,340 <PREFERRED-MANDATORY> 0 <PREFERRED> 0 <COMMON> 65,291 <OTHER-SE> 1,030,263 <TOTAL-LIABILITY-AND-EQUITY> 1,397,273 <SALES> 598,048 <TOTAL-REVENUES> 598,048 <CGS> 321,673 <TOTAL-COSTS> 321,673 <OTHER-EXPENSES> 167,470 <LOSS-PROVISION> 1,275 <INTEREST-EXPENSE> 13 <INCOME-PRETAX> (7,710) <INCOME-TAX> (2,775) <INCOME-CONTINUING> (4,935) <DISCONTINUED> 0 <EXTRAORDINARY> 0 <CHANGES> 0 <NET-INCOME> (4,935) <EPS-BASIC> (0.04) <EPS-DILUTED> (0.04)